Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2010

Conditions
Head and Neck Cancer
Interventions
DRUG

oxaliplatin

"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."

DRUG

pemetrexed disodium

"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."

Trial Locations (7)

37064

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville

Vanderbilt-Ingram Cancer Center at Franklin, Nashville

37208

MBCCOP - Meharry Medical College - Nashville, Nashville

38301

West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson

42002

Purchase Cancer Group - Paducah, Paducah

42303

Mitchell Memorial Cancer Center at Owensboro Medical Health System, Owensboro

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00503997 - Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer | Biotech Hunter | Biotech Hunter